Premium
Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions
Author(s) -
Zhu Jing,
Yin Tailang,
Xu Yong,
Lu XiaoJie
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.28048
Subject(s) - hepatocellular carcinoma , medicine , dilemma , radiation therapy , immunotherapy , transcatheter arterial chemoembolization , intensive care medicine , targeted therapy , oncology , cancer , philosophy , epistemology
Abstract Hepatocellular carcinoma (HCC) is one of the most common malignancies and is a serious threat to people's health worldwide. The prognosis of advanced HCC is dim if left untreated. In the clinic, the treatment options for advanced HCC include surgery, radiotherapy, transcatheter arterial chemoembolization, and so forth. In recent years, molecular targeted therapy and immunotherapy have also made great progress, bringing new hope to patients with advanced HCC. In this study, therapeutic advances, current dilemma, and future directions of advanced HCC are reviewed, which might serve as a summary for clinicians and may stimulate future research.